Combined effect of celecoxib and glucosamine sulfate on inflammatory factors and oxidative stress indicators in patients with knee osteoarthritis

Deng, Gang; Chen, Xiaguang; Kanghua, Yang; Wu, Xia; Zeng, Guangxuan

doi:10.4314/tjpr.v18i2.25

Cited by 6 publications

(5 citation statements)

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of clinical studies reported that the combination of celecoxib and GS effectively modulate immune inflammatory response, oxidative stress damage, and joint pain and function in patients with knee OA [70][71][72]. Our results demonstrate, for the first time, the synergistic effect of celecoxib and GS on human OA chondrocyte metabolism.…”

Section: Discussionsupporting

confidence: 52%

A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflammatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteoarthritic Chondrocytes

Cheleschi

Tenti

Giannotti

et al. 2021

IJMS

View full text Add to dashboard Cite

This study investigated the possible anti-inflammatory and chondroprotective effects of a combination of celecoxib and prescription-grade glucosamine sulfate (GS) in human osteoarthritic (OA) chondrocytes and their possible mechanism of action. Chondrocytes were treated with celecoxib (1.85 µM) and GS (9 µM), alone or in combination with IL-1β (10 ng/mL) and a specific nuclear factor (NF)-κB inhibitor (BAY-11-7082, 1 µM). Gene expression and release of some pro-inflammatory mediators, metalloproteinases (MMPs), and type II collagen (Col2a1) were evaluated by qRT-PCR and ELISA; apoptosis and mitochondrial superoxide anion production were assessed by cytometry; B-cell lymphoma (BCL)2, antioxidant enzymes, and p50 and p65 NF-κB subunits were analyzed by qRT-PCR. Celecoxib and GS alone or co-incubated with IL-1β significantly reduced expression and release of cyclooxygenase (COX)-2, prostaglandin (PG)E2, IL-1β, IL-6, tumor necrosis factor (TNF)-α, and MMPs, while it increased Col2a1, compared to baseline or IL-1β. Both drugs reduced apoptosis and superoxide production; reduced the expression of superoxide dismutase, catalase, and nuclear factor erythroid; increased BCL2; and limited p50 and p65. Celecoxib and GS combination demonstrated an increased inhibitory effect on IL-1β than that observed by each single treatment. Drugs effects were potentiated by pre-incubation with BAY-11-7082. Our results demonstrated the synergistic effect of celecoxib and GS on OA chondrocyte metabolism, apoptosis, and oxidative stress through the modulation of the NF-κB pathway, supporting their combined use for the treatment of OA.

show abstract

Section: Discussionsupporting

confidence: 52%

A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflammatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteoarthritic Chondrocytes

Cheleschi

Tenti

Giannotti

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…This study showed that the combination of pCGS and celecoxib significantly reduced the levels of inflammatory and oxidative stress parameters and markedly lowered pain scores. This supports a possible synergistic role in inhibiting the progression of OA and improving joint function [33]. An RCT conducted by Sun and colleagues compared the use of pCGS and etoricoxib versus etoricoxib alone.…”

Section: Synergistic Effect Of Nsaids and Symptomatic Slow-acting Dru...mentioning

confidence: 81%

“…Two randomized controlled trials (RCTs) were designed to evaluate the reparative effects of combination therapy with pCGS and NSAIDs in patients with knee OA. In the study by Gang and colleagues, 120 patients with knee OA were randomized to two groups, with the intervention group treated with a combination of pCGS (a total of 1500 mg/day) and celecoxib (200 mg/day), while the control group received celecoxib alone (200 mg/day) [ 33 ]. This study showed that the combination of pCGS and celecoxib significantly reduced the levels of inflammatory and oxidative stress parameters and markedly lowered pain scores.…”

Section: Synergistic Effect Of Nsaids and Symptomatic Slow-acting Dru...mentioning

confidence: 99%

Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations

Veronese

Cooper

Bruyère

et al. 2022

Drugs

View full text Add to dashboard Cite

Knee osteoarthritis (OA) is one of the most common and disabling medical conditions. In the case of moderate to severe pain, a single intervention may not be sufficient to allay symptoms and improve quality of life. Examples include first-line, background therapy with symptomatic slow-acting drugs for OA (SYSADOAs) or non-steroidal anti-inflammatory drugs (NSAIDs). Therefore, the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) performed a review of a multimodal/multicomponent approach for knee OA therapy. This strategy is a particularly appropriate solution for the management of patients affected by knee OA, including those with pain and dysfunction reaching various thresholds at the different joints. The multimodal/multicomponent approach should be based, firstly, on different combinations of non-pharmacological and pharmacological interventions. Potential pharmacological combinations include SYSADOAs and NSAIDs, NSAIDs and weak opioids, and intra-articular treatments with SYSADOAs/NSAIDs. Based on the available evidence, most combined treatments provide benefit beyond single agents for the improvement of pain and other symptoms typical of knee OA, although further high-quality studies are required. In this work, we have therefore provided new, patient-centered perspectives for the management of knee OA, based on the concept that a multimodal, multicomponent, multidisciplinary approach, applied not only to non-pharmacological treatments but also to a combination of the currently available pharmacological options, will better meet the needs and expectations of patients with knee OA, who may present with various phenotypes and trajectories.

show abstract

“…In an RCT including elderly people with temporomandibular joint OA, treatment with an intra-articular hyaluronic acid injection in combination with glucosamine hydrochloride (oral 720 mg for 3 months) was shown to be greatly beneficial by further reducing the IL-6, IL-1β, and TGF-β levels if compared with people treated with only hyaluronic acid injection [ 55 ]. Glucosamine sulphate (1500 mg/day) in addition with celecoxib (200 mg/day) supplemented in patients with knee OA for 8 weeks showed a better redox status expressed as higher serum SOD activity and lower serum MDA levels compared with the control group (celecoxib alone) [ 56 ].…”

Section: Nutraceuticals Used For the Prevention Of Worsening And Management Of Oamentioning

confidence: 99%

Nutraceutical Approach to Chronic Osteoarthritis: From Molecular Research to Clinical Evidence

Colletti

Cicero

2021

IJMS

View full text Add to dashboard Cite

Osteoarthritis (OA) is a degenerative inflammatory condition of the joint cartilage that currently affects approximately 58 million adults in the world. It is characterized by pain, stiffness, and a reduced range of motion with regard to the arthritic joints. These symptoms can cause in the long term a greater risk of overweight/obesity, diabetes mellitus, and falls and fractures. Although the current guidelines for the treatment of OA suggest, as the gold standard for this condition, pharmacological treatment characterized by non-steroidal anti-inflammatory drugs (NSAID), opioids, and cyclooxygenase (COX)-2-specific drugs, a great interest has been applied to nutraceutical supplements, which include a heterogeneous class of molecules with great potential to reduce inflammation, oxidative stress, pain, and joint stiffness and improve cartilage formation. The purpose of this review is to describe the potential application of nutraceuticals in OA, highlighting its molecular mechanisms of actions and data of efficacy and safety (when available).

show abstract

Combined effect of celecoxib and glucosamine sulfate on inflammatory factors and oxidative stress indicators in patients with knee osteoarthritis

Cited by 6 publications

References 5 publications

A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflammatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteoarthritic Chondrocytes

A Combination of Celecoxib and Glucosamine Sulfate Has Anti-Inflammatory and Chondroprotective Effects: Results from an In Vitro Study on Human Osteoarthritic Chondrocytes

Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations

Nutraceutical Approach to Chronic Osteoarthritis: From Molecular Research to Clinical Evidence

Contact Info

Product

Resources

About